Moderna and Merck & Co. announced that their experimental mRNA‑4157 vaccine against melanoma met its primary endpoints in a large, registration‑size trial, making it the first mRNA‑based drug to succeed in a pivotal cancer study.
Why the trial matters
The study, described by the companies as “approval‑relevant”, enrolled patients with high‑risk melanoma and measured recurrence‑free survival. Meeting the primary endpoints means the data are sufficient for regulators to consider a marketing‑authorisation filing, a step that goes far beyond the early‑phase signals that have characterised most oncology mRNA programmes.
“It is the first mRNA‑based drug to demonstrate efficacy in a large, registration‑relevant cancer trial,” the Handelsblatt report notes. The result validates the broader hypothesis that messenger‑RNA technology, which proved its speed and scalability during the COVID‑19 pandemic, can be repurposed for personalised oncology treatments.
Deal structure and strategic stakes
Moderna and Merck & Co. entered the partnership in 2021, combining Moderna’s mRNA platform with Merck’s oncology expertise and commercial network. The collaboration is structured as a co‑development and co‑commercialisation agreement, with each party sharing development costs and future profits in proportion to their contributions. While the exact financial terms have not been disclosed, the joint effort reflects a broader trend of biotech firms partnering with large pharma to de‑risk high‑cost oncology programmes.
Both companies stand to benefit. Moderna, whose revenue in 2023 was $2.21 bn but which posted a net loss of $2.13 bn in the first half of 2026, is seeking a post‑COVID growth engine. Merck, with 2026 revenue of $32.9 bn, is looking to diversify beyond its blockbuster cancer drugs such as Keytruda.
Market expectations and valuation upside
Wall Street analysts, citing the trial’s success, now project a market launch as early as 2027. The consensus view is that the vaccine could generate “multi‑billion‑dollar” sales, though no firm figure has been published. The optimism stems from two factors: the high unmet need in melanoma, where recurrence rates remain significant despite existing therapies, and the premium pricing that novel, personalised cancer treatments typically command.
Analysts also note that the vaccine’s mechanism – encoding patient‑specific neoantigens – could be adapted to other solid tumours, potentially expanding the addressable market well beyond melanoma. If the product reaches the market on schedule, it would be the first mRNA‑based oncology therapy, giving Moderna and Merck a first‑mover advantage that could translate into a valuation premium for both stocks.
Sector backdrop and comparable precedents
The biotech sector has seen a wave of mRNA‑focused deals since 2020. BioNTech’s partnership with Pfizer to develop mRNA cancer vaccines, for example, has yielded several early‑stage trials but none have yet cleared a pivotal efficacy hurdle. In contrast, the Moderna‑Merck vaccine’s success places it ahead of peers such as GSK’s mRNA oncology pipeline, which remains in Phase 1/2.
From a financial perspective, the market has rewarded companies that achieve regulatory milestones. When Moderna’s COVID‑19 vaccine received emergency use authorisation in late 2020, its share price surged more than 150 % over the following year. While the oncology market dynamics differ, the precedent suggests that a successful filing could lift both companies’ equities, especially if the product is positioned as a premium, personalised therapy.
What comes next – milestones and unknowns
The next regulatory step is a filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration, likely in 2026. Parallel submissions to the European Medicines Agency are expected, given the trial’s multinational enrolment, including sites in Germany.
Key milestones are summarised in the table below.
| Milestone | Expected timing | Source |
|---|---|---|
| FDA Biologics License Application (BLA) submission | Late 2026 | Handelsblatt |
| EMA marketing‑authorisation filing | Early 2027 | Handelsblatt |
| Projected US market launch | 2027 | Handelsblatt |
| Projected EU market launch | 2027‑2028 | Handelsblatt |
| First‑year sales forecast (range) | Billions of USD (exact figure not disclosed) | Handelsblatt |
Despite the optimism, several uncertainties remain. First, the FDA may request additional data on long‑term safety, especially given the novelty of mRNA‑based oncology products. Second, manufacturing capacity for personalised vaccines is still being scaled; any bottleneck could delay launch. Third, reimbursement pathways for high‑cost, patient‑specific therapies are not yet standardised in many markets, potentially affecting pricing power.
Finally, competition could intensify if other mRNA developers achieve pivotal success before 2027. The sector’s rapid pace means that a first‑mover advantage is not guaranteed to last.
Implications for investors
For founders and investors tracking biotech deals, the Moderna‑Merck collaboration illustrates how a high‑risk, high‑cost bet can shift from scepticism to market‑potential within a single quarter. The positive data turned “widespread scepticism into optimism,” a narrative that can drive capital inflows and elevate share prices.
Investors should watch the upcoming BLA filing closely. A successful filing would likely trigger a re‑rating of both companies, especially Moderna, whose pipeline diversification is a key strategic objective. Conversely, a delay or request for further data could temper enthusiasm and expose the companies to valuation volatility.
In the broader context, the episode underscores the growing relevance of mRNA beyond infectious disease. If the vaccine reaches patients in 2027, it could open a new revenue stream that rivals existing oncology blockbusters, reshaping the competitive landscape for both biotech innovators and legacy pharma.